We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Aptamera, a three-year-old Louisville biotechnology company that is working
to develop anticancer drugs, has agreed to be acquired by Antisoma, a biotechnology
firm based in the UK.
Perlegen Sciences will commence a pharmacogenomics
collaboration with Johnson & Johnson Pharmaceutical Research and Development
(J&JPRD), a Johnson & Johnson company.
Prompted by a request from Wyeth, the FDA has reopened the public comment period
for two International Conference on Harmonisation (ICH) draft guidances that
assess possible cardiac risks associated with new drugs.
Federal securities class action lawsuits involving product liability claims,
such as those filed against Merck and Pfizer, may represent a growing trend
in the class action field, according to a new report.
A Democratic congressman has asked the FDA to investigate what it knew about
certain Eli Lilly documents from the mid-1980s that allegedly showed a link
between suicidal behavior and the antidepressant Prozac.
Sunesis Pharmaceuticals announced today that it has extended its research collaboration
with Johnson & Johnson Pharmaceutical Research & Development through
the end of 2005.
KV Pharmaceutical announced today that it has entered into agreements with Representaciones
E Investigaciones Medica for the granting of licensing rights in Mexico for
KV's two single dose prescription vaginal cream products, U.S. market leader
Gynazole-1 and the recently FDA-approved Clindesse.
Isis Pharmaceuticals on Monday said it is cutting its work force by about 40
percent as part of a move to reduce costs and focus on developing its most advanced
experimental drugs and technology.